Overview
IMMP market data
Price History
IMMP price chart
Valuation & Profitability
- P/E (TTM)
- — Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- -$0.04 Diluted earnings per share over the trailing twelve months.
- Beta
- 3.03 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- — Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- — Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $0.03 – $0.47 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- — Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · source Twelve Data /statistics · market cap $75.2 · P/B 2.44 · P/S 18.19.
Company news
Correction: Head and Neck Squamous Cell Carcinoma Market is Projected to Boost at a CAGR of 10.5% During the Forecast Period (2026–2036) Due to the Launch of Emerging Novel Immunotherapies | DelveInsightGlobenewswire Inc · Jul 21, 2026, 6:30 PM
Immutep Secures United States Patent No. 12,673,088 Titled "Combined Preparations for the Treatment of Cancer or Infection"Benzinga · Jul 14, 2026, 12:05 PM
Head and Neck Squamous Cell Carcinoma Market is Projected to Boost at a CAGR of 10.5% During the Forecast Period (2026–2036) Due to the Launch of Emerging Novel Immunotherapies | DelveInsightGlobenewswire Inc · Jul 13, 2026, 5:15 PM
Immutep Announces Positive Update For Phase I Trial Evaluation Of Eftilagimod AlfaBenzinga · Jul 13, 2026, 12:05 PM
Robbins LLP Reminds IMMP Investors of the Pending Class Action Lawsuit; Harmed Investors Should Contact the Firm for Information About Leading the Class Action Against Immutep LimitedGlobenewswire Inc · Jun 5, 2026, 6:15 PM
Robbins LLP Reminds LKQ Investors of the Pending Class Action Lawsuit; Harmed Investors Should Contact the Firm for Information About Leading the Class Action Against LKQ CorporationGlobenewswire Inc · Jun 5, 2026, 6:15 PM
Immutep to Present Positive Interim Phase I Data for IMP761, a First-in-Class LAG-3 Agonist Antibody, at EULAR 2026Globenewswire Inc · Jun 4, 2026, 12:15 PM
Immutep To Present Interim Phase I Data For IMP761 At EULAR 2026Benzinga · Jun 4, 2026, 12:10 PM
Immutep Announces Results From Systematic Evaluation Of 5 Clinical Trials Of Eftilagimod Alfa APC Activator In Combination With Standard-Of-Care Therapies In Late-Stage Cancer PatientsBenzinga · May 28, 2026, 12:25 PM